Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda.
Rwanda
childhood cancers
registry
stage
survival
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
26 Apr 2024
26 Apr 2024
Historique:
revised:
28
03
2024
received:
18
11
2023
accepted:
02
04
2024
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
26
4
2024
Statut:
aheadofprint
Résumé
The lack of accurate population-based information on childhood cancer stage and survival in low-income countries is a barrier to improving childhood cancer outcomes. In this study, data from the Rwanda National Cancer Registry (RNCR) were examined for children aged 0-14 diagnosed in 2013-2017 for the eight most commonly occurring childhood cancers: acute lymphoblastic leukaemia, Hodgkin lymphoma (HL), Burkitt lymphoma (BL), non-Hodgkin lymphoma excluding BL, retinoblastoma, Wilms tumour, osteosarcoma and rhabdomyosarcoma. Utilising the Toronto Childhood Cancer Stage Guidelines Tier 1, the study assigned stage at diagnosis to all, except HL, and conducted active follow-ups to calculate 1-, 3- and 5-year observed and relative survival by cancer type and stage at diagnosis. The cohort comprised 412 children, of whom 49% (n = 202) died within 5 years of diagnosis. Five-year survival ranged from 28% (95% confidence interval [CI]: 12.5%-45.6%) for BL to 68% (CI: 55%-78%) for retinoblastoma. For the cancers for which staging was carried out, it was assigned for 83% patients (n = 301 of 362), with over half (58%) having limited or localised stage at diagnosis. Stage was a strong predictor of survival; for example, 3-year survival was 70% (95% CI: 45.1%-85.3%) and 11.8% (2.0%-31.2%) for limited and advanced non-HL, respectively (p < .001). This study is only the second to report on stage distribution and stage-specific survival for childhood cancers in sub-Saharan Africa. It demonstrates the feasibility of the Toronto Stage Guidelines in a low-resource setting, and highlights the value of population-based cancer registries in aiding our understanding of the poor outcomes experienced by this population.
Sections du résumé
BACKGROUND
BACKGROUND
The lack of accurate population-based information on childhood cancer stage and survival in low-income countries is a barrier to improving childhood cancer outcomes.
METHODS
METHODS
In this study, data from the Rwanda National Cancer Registry (RNCR) were examined for children aged 0-14 diagnosed in 2013-2017 for the eight most commonly occurring childhood cancers: acute lymphoblastic leukaemia, Hodgkin lymphoma (HL), Burkitt lymphoma (BL), non-Hodgkin lymphoma excluding BL, retinoblastoma, Wilms tumour, osteosarcoma and rhabdomyosarcoma. Utilising the Toronto Childhood Cancer Stage Guidelines Tier 1, the study assigned stage at diagnosis to all, except HL, and conducted active follow-ups to calculate 1-, 3- and 5-year observed and relative survival by cancer type and stage at diagnosis.
RESULTS
RESULTS
The cohort comprised 412 children, of whom 49% (n = 202) died within 5 years of diagnosis. Five-year survival ranged from 28% (95% confidence interval [CI]: 12.5%-45.6%) for BL to 68% (CI: 55%-78%) for retinoblastoma. For the cancers for which staging was carried out, it was assigned for 83% patients (n = 301 of 362), with over half (58%) having limited or localised stage at diagnosis. Stage was a strong predictor of survival; for example, 3-year survival was 70% (95% CI: 45.1%-85.3%) and 11.8% (2.0%-31.2%) for limited and advanced non-HL, respectively (p < .001).
CONCLUSION
CONCLUSIONS
This study is only the second to report on stage distribution and stage-specific survival for childhood cancers in sub-Saharan Africa. It demonstrates the feasibility of the Toronto Stage Guidelines in a low-resource setting, and highlights the value of population-based cancer registries in aiding our understanding of the poor outcomes experienced by this population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31020Subventions
Organisme : Vital Strategies, Global Grants Program
Organisme : Bloomberg Philanthropies Data for Health Initiative
ID : 39
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Steliarova‐Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001–10: a population‐based registry study. Lancet Oncol. 2017;18(6):719‐731. doi:10.1016/S1470‐2045(17)30186‐9
Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and priority‐setting: a simulation‐based analysis. Lancet Oncol. 2019;20(7):972‐983. doi:10.1016/S1470‐2045(19)30273‐6
Pritchard‐Jones K, de Abib SCV, Esiashvili N, et al. The threat of the COVID‐19 pandemic on reversing global life‐saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, st jude global, UICC and WHPCA. Ecancermedicalscience. 2021;15:1187. doi:10.3332/ECANCER.2021.1187
Pineros M, Mery L, Soerjomataram I, Bray F, Steliarova‐Foucher E. Scaling up the surveillance of childhood cancer: a global roadmap. J Natl Cancer Inst. 2021;113(1):9‐15. doi:10.1093/JNCI/DJAA069
Joko‐Fru WY, Parkin DM, Borok M, et al. Survival from childhood cancers in Eastern Africa: a population‐based registry study. Int J Cancer. 2018;143(10):2409‐2415. doi:10.1002/ijc.31723
Liu B, Youlden DR, Wabinga H, et al. Survival from childhood cancer in Kampala, Uganda. Pediatr Blood Cancer. 2021;68(3):e28876. doi:10.1002/pbc.28876
Gupta S, Aitken JF, Bartels U, et al. Paediatric cancer stage in population‐based cancer registries: the Toronto consensus principles and guidelines. Lancet Oncol. 2016;17(4):e163‐e172. doi:10.1016/S1470‐2045(15)00539‐2
Steliarova‐foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103(7):1457‐1467. doi:10.1002/cncr.20910
Aitken JF, Youlden D, O'Neill L, Gupta S, Frazier AL. Childhood cancer staging rules for population based registries Toronto childhood cancer stage guidelines (version 2). African Cancer Registry Network; 2021. https://cancerqld.blob.core.windows.net/content/docs/childhood‐cancer‐staging‐for‐population‐registries.pdf
Parkin DM, Youlden DR, Chitsike I, et al. Stage at diagnosis and survival by stage for the leading childhood cancers in three populations of sub‐Saharan Africa. Int J Cancer. 2021;148(11):2685‐2691. doi:10.1002/ijc.33468
Chakumatha E, Weijers J, Banda K, et al. Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. Pediatr Blood Cancer. 2020;67(7):e28322. doi:10.1002/pbc.28322
McGoldrick SM, Mutyaba I, Adams SV, et al. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda. Pediatr Blood Cancer. 2019;66(9):e27813. doi:10.1002/pbc.27813
Buckle G, Maranda L, Skiles J, et al. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: a historical cohort study. Int J Cancer. 2016;139(6):1231‐1240. doi:10.1002/ijc.30170
Goolam S, Kana H, Welsh N, Wainwright L, Poole J, Mayet I. A 20‐year retrospective review of retinoblastoma at two tertiary academic hospitals in Johannesburg, South Africa. Ocul Oncol Pathol. 2018;4(3):170‐175. doi:10.1159/000481508
Mutyaba I, Wabinga HR, Orem J, Casper C, Phipps W. Presentation and outcomes of childhood cancer patients at Uganda Cancer Institute. Glob Pediatr Heal. 2019;6:2333794X1984974. doi:10.1177/2333794X19849749
Yao AJJ, Moreira C, Traoré F, et al. Treatment of wilms tumor in sub‐Saharan Africa: results of the second French African pediatric oncology group study. J Glob Oncol. 2019;2019(5):1‐8. doi:10.1200/JGO.18.00204
Liu B, Abraham N, Chitsike I, et al. Enhancing information on stage at diagnosis for childhood cancer in Africa. Pediatr Blood Cancer. 2023;70(10):e30555. doi:10.1002/pbc.30555
Youlden DR, Frazier AL, Gupta S, et al. Stage at diagnosis for childhood solid cancers in Australia: a population‐based study. Cancer Epidemiol. 2019;59:208‐214. doi:10.1016/j.canep.2019.02.013
Gatta G, Botta L, Capocaccia R, et al. Staging childhood cancers in Europe: application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study. Pediatr Blood Cancer. 2021;68(9):e29020. doi:10.1002/pbc.29020
Traoré F, Sylla F, Togo B, et al. Treatment of retinoblastoma in sub‐Saharan Africa: experience of the paediatric oncology unit at Gabriel Toure Teaching Hospital and the Institute of African Tropical Ophthalmology, Bamako, Mali. Pediatr Blood Cancer. 2018;65(8):e27101. doi:10.1002/pbc.27101
Youlden DR, Gupta S, Frazier AL, et al. Stage at diagnosis for children with blood cancers in Australia: application of the Toronto Paediatric Cancer Stage Guidelines in a population‐based national childhood cancer registry. Pediatr Blood Cancer. 2019;66(6):e27683. doi:10.1002/pbc.27683
Howlader N, Noone AM, Krapcho M, et al., eds. SEER cancer statistics review, 1975–2018. National Cancer Institute. Bethesda, MD. Released April 15, 2021. https://seer.cancer.gov/archive/csr/1975_2018/index.html
Botta L, Gatta G, Capocaccia R, et al. Long‐term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE‐6): results from a population‐based study. Lancet Oncol. 2022;23(12):1525‐1536. doi:10.1016/S1470‐2045(22)00637‐4
Kanyamuhunga A, Tuyisenge L, Stefan DC. Treating childhood cancer in Rwanda: the nephroblastoma example. Pan Afr Med J. 2015;21:326. 10.11604/pamj.2015.21.326.5912